Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rifapentine pharmacokinetics in adolescents.

J D Marshall1, S Abdel-Rahman, K Johnson

  • 1Department of Pediatrics, University of Missouri-Kansas City, USA. jmarshall@cmh.edu

The Pediatric Infectious Disease Journal
|October 26, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exposure to Smoke From Wildfire, Prescribed, and Agricultural Burns Among At-Risk Populations Across Washington, Oregon, and California.

GeoHealth·2024
Same author

Morphological changes and photosynthate allocation in ageing Hebeloma crustuliniforme (Bull.) Quel. and Laccaria bicolor (Maire) Orton mycorrhizas of Pinus ponderosa Dougl. ex. Laws.

The New phytologist·2021
Same author

Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity.

Pediatric obesity·2018
Same author

Performance of low-cost monitors to assess household air pollution.

Environmental research·2018
Same author

Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders.

Alimentary pharmacology & therapeutics·2018
Same author

Altitude trends in conifer leaf morphology and stable carbon isotope composition.

Oecologia·2017

Rifapentine demonstrated favorable pharmacokinetics in adolescents, achieving rapid and sustained plasma concentrations. This suggests it is a well-tolerated and effective treatment option for tuberculosis in this age group.

Area of Science:

  • Pharmacology
  • Clinical Pharmacology
  • Adolescent Medicine

Background:

  • Rifapentine is a key antibiotic for treating tuberculosis.
  • Understanding its pharmacokinetic profile in adolescents is crucial for effective dosing and treatment strategies.
  • Limited data exists on rifapentine pharmacokinetics specifically in the pediatric population.

Purpose of the Study:

  • To determine the pharmacokinetic profile of rifapentine in healthy adolescent children.
  • To assess the safety and tolerability of a single oral dose of rifapentine in this age group.
  • To compare adolescent rifapentine pharmacokinetics with existing data in adult populations.

Main Methods:

  • A prospective Phase II clinical trial was conducted.
  • Twelve healthy adolescents (aged 12-15 years) received a single oral dose of rifapentine (450 mg or 600 mg based on weight).

Related Experiment Videos

  • Plasma concentrations of rifapentine and its metabolite, 25-desacetyl rifapentine, were measured using high-pressure liquid chromatography at serial time points.

    • Main Results:

    • Rifapentine was well-tolerated with no adverse effects reported in any subject.
    • Achieved plasma concentrations of rifapentine and its metabolite significantly exceeded the minimum inhibitory concentration for Mycobacterium tuberculosis.
    • High Cmax and a long terminal elimination half-life (t1/2) indicated sustained effective drug concentrations for at least 48 hours.

    Conclusions:

    • A single oral dose of rifapentine produces rapid and sustained plasma concentrations in adolescents.
    • These concentrations are expected to effectively treat Mycobacterium tuberculosis infections.
    • Rifapentine pharmacokinetics in adolescents appear comparable to those observed in adult populations.